FDA sets back Novartis plans to expand use of SMA gene therapy

Submitted by admin on September 23, 2020 - 10:39am

Source:

BioPharma Dive

News Tags:

Novartis

SMA

gene therapy

Zolgensma

clinical trials

FDA

Headline:

FDA sets back Novartis plans to expand use of SMA gene therapy

snippet:

Novartis has to run a new clinical trial before it can seek U.S. approval for an experimental formulation of its spinal muscular atrophy gene therapy Zolgensma, the Swiss drugmaker said Wednesday, in the latest setback to its plans to treat older patients with the neuromuscular disease.

Search form

You are here

FDA sets back Novartis plans to expand use of SMA gene therapy

FDA sets back Novartis plans to expand use of SMA gene therapy